What is the quality of evidence for the effects of dual RASi therapy compared to monotherapy on all-cause mortality, CV events and ESKD?
The overall quality of the evidence for harm was moderate. The network meta-analysis that compared dual RASi with mono RASi exhibited moderate quality of the evidence because of concerns regarding inconsistency for all-cause mortality and CV events and serious imprecision for ESKD due to wide CIs that indicated appreciable bene ts and harms (Supplementary Table S32).169 The ERT review (including Cochrane reviews that were updated259,281 ) rated the quality of evidence to be moderate for studies that compared dual with mono RASi because of study limitations, with unclear reporting for Cochrane risk of bias282 domains, random sequence generation, and allocation concealment (Supplementary Table S31234,277 279,283,284 ).